Study: Why people with knee osteoarthritis experience different kinds of pain

Osteoarthritis is the most common form of arthritis worldwide, affecting more than 300 million people. It causes substantial pain, functional limitations, and disability in patients.

"Our findings support the clinical relevance of neurobiological mechanisms that affect the pain experience in knee osteoarthritis, including not only the severity of pain, but whether the pain is intermittent or constant, and whether the pain is unpredictable," said senior author Tuhina Neogi, MD, Ph.D., professor of medicine and epidemiology at Boston University School of Medicine.

Read the news article

Read the published article

The Association of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis

First published: 03 September 2020

Tuhina Neogi, MD, PhD, National Leader in Gout Management, on New ACR Guidelines

Coauthor of the first guidance update since 2012 talks about new recommendations


by Scott Harris
Contributing Writer, MedPage Today
MedPage Today and the American College of Rheumatology

For the first time in eight years, the American College of Rheumatology (ACR) has updated its guidelines for the effective management of gout.

Tuhina Neogi, MD, PhD, chief of rheumatology at Boston Medical Center, served as a coauthor of the 2020 American College of Rheumatology Guideline for the Management of Gout, which was simultaneously published in Arthritis & Rheumatology and Arthritis Care and Research. She recently spoke with MedPage Today about the document and its recommendations.

Read the article


In the News: Relation of Oral Bisphosphonates to Bone Marrow Lesion Volume among Women with Osteoarthritis

In the News - Tuhina Neogi publication - Bone drug may be beneficial in the treatment of OA

Ballal, P., et al. (2020) The Relation of Oral Bisphosphonates to Bone Marrow Lesion Volume among Women with Osteoarthritis. Osteoarthritis and Cartilage.

"When we looked at those who had bone marrow lesions at baseline, we found that the women who started bisphosphonates had had more bone marrow lesions that decreased in size than the women who did not start bisphosphonates. These results suggest that bisphosphonates do not appear to be harmful, at least over one year, and perhaps may even help decrease bone marrow lesions in those that have them."

Tuhina Neogi, MD, PhD, corresponding author, Professor of Medicine and Epidemiology at Boston University Schools of Medicine and Public Health

In the News: Tuhina Neogi on updated Guidelines for Management of Patients with Gout

New recommendations for the management of patients with gout were presented in draft form at the 2019 American College of Rheumatology (ACR) Annual Meeting. The ACR Practice Guidelines Committee determined that it was necessary to update the 2012 version of the guidelines, based on new evidence from clinical trials. The new guidelines are currently under peer review and the committee is hoping to have them published sometime in 2020.


Andreea Bujor receives RRF Investigator Award with the Malawista designation

Dr. Andreea Bujor, Assistant Professor in Rheumatology, has received a 3-year Investigator Award from the Rheumatology Research Foundation.

Andreea’s research, titled “The role of myeloid Fli1 in organ fibrosis in scleroderma,” will address an unanswered question regarding scleroderma heart fibrosis: whether monocytes/macrophages contribute to the disease pathogenesis.  The study systematically examines the contribution of the decrease transcription factor Fli1 in monocytes/macrophages to fibrosis in vivo and in vitro.

This analysis will determine whether future treatments in scleroderma, including treatment for scleroderma cardiomyopathy, should target Fli1 and the myeloi system, thus providing the basis for potentially safer, more effective therapies.

Annually, the Foundation’s Scientific Advisory Council chooses an outstanding recipient to receive the Malawista designation. We are excited to announce that Dr. Bujor has been named the recipient of the Tobé and Stephen E. Malawista, MD, Endowment in Academic Rheumatology. You can read more about this endowment here.

In the News: Tuhina Neogi in RheumNow

?php print t('Home'); ?>

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

In the CANVAS clinical trial program, which was funded by Janssen Research & Development and included more than 10,000 patients, the percentage difference in serum urate reduction with canagliflozin versus placebo was 6.7% (95% CI -7.3 to -6.1), according to Bruce Neal, MBChB, PhD, of the University of Sydney in Australia, and colleagues.

In addition, the likelihood of a gout flare or the initiation of treatment for gout was halved in patients treated with canagliflozin, with a hazard ratio of 0.53 (95% CI 0.40 to 0.71, P<0.0001), the researchers reported online in The Lancet Rheumatology.

“This agent appears to show potential for being a dual-benefit gout therapy, lowering serum urate and providing potential flare prophylaxis and thereby potentially reducing the need for separate flare prophylaxis with agents that are often contraindicated or poorly tolerated in patients with gout,” wrote Tuhina Neogi, MD, PhD, chief of rheumatology at Boston University School of Medicine, in an accompanying comment.

Read the full article in RheumNow